Bausch Health Companies Inc.

Bausch Health Companies Inc. ( we , us , our , the Company or Bausch Health ) is a global, diversified specialty pharmaceutical and medical device company that develops, manufactures and markets, primarily in the therapeutic areas of gastroenterology ( GI ), hepatology, neurology and dermatology, a broad range of branded, generic and branded generic pharmaceuticals, over-the-counter ( OTC ) products and aesthetic medical devices and, through our approximately 88% ownership of Bausch + Lomb Corporation ( Bausch + Lomb or B+L ), branded, and branded generic pharmaceuticals, OTC products and medical devices (contact lenses, intraocular lenses, ophthalmic surgical equipment) in the therapeutic areas of eye health. The Company’s products are marketed directly or indirectly in approximately 90 countries. Our portfolio of products falls into five reportable segments: (i) Salix, (ii) International, (iii) Solta Medical, (iv) Diversified and (v) Bausch + Lomb. The following is a brief description of the Company’s segments: The Salix segment consists of sales in the U.S. of GI products. Sales of the Xifaxan product line currently represent approximately 85% of the Salix segment revenues. The International segment consists of sales, with the exception of sales of Bausch + Lomb products and Solta Medical aesthetic medical devices, outside the U.S. of branded pharmaceutical products, branded generic pharmaceutical products and OTC products. The Solta Medical segment consists of global sales of Solta Medical aesthetic medical devices. The Diversified segment consists of sales in the U.S.